<DOC>
	<DOCNO>NCT01782989</DOCNO>
	<brief_summary>This prospective , randomize study evaluate efficacy safety ORACEA® treatment geographic atrophy due dry age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Clinical Study Evaluate Treatment With ORACEA® Geographic Atrophy ( TOGA )</brief_title>
	<detailed_description>Eligible participant complete 6-month Observation Phase , follow 24-month Treatment Phase , follow End Study Visit . Eligible participant randomize Month 6 1:1 ratio either ORACEA ( 40 mg doxycycline ) placebo capsule take once-daily 24 month . Over course 31-month study , total 9 clinic visit 3 telephone call require .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Male female , age &gt; /=55 year Best correct visual acuity 20/20 20/400 study eye Best correct visual acuity hand motion well nonstudy eye Clinical diagnosis geographic atrophy secondary nonexudative agerelated macular degeneration least one eye ( study eye ) Geographic atrophy lesion ≥ 0.5 ≤ 7.0 MPS disc area History active presence choroidal neovascularization secondary exudative agerelated macular degeneration study eye History active presence choroidal neovascularization secondary exudative agerelated macular degeneration nonstudy eye require treatment within 12 month prior Day 0 expect require treatment duration study Prior treatment nonexudative agerelated macular degeneration Current previous history treatment study eye tetracycline derivative ocular condition . History vitreoretinal surgery , corneal transplant , laser photocoagulation study eye Any intraocular periocular surgery within 90 day prior Day 0 study eye . History hypersensitivity tetracycline component Use tetracycline derivative therapy concurrent systemic ocular disorder within 90 day Day 0 History sensitivity sun</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>geographic atrophy</keyword>
	<keyword>non-exudative age-related macular degeneration</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>dry macular degeneration</keyword>
	<keyword>dry AMD</keyword>
</DOC>